4 citations
,
February 2013 in “Revista De Saude Publica” This article examines the public health risks and benefits of pill organizers and cutters, concluding that healthcare professionals should guide their use to prevent potential medication stability and efficacy issues.
November 2022 in “Zenodo (CERN European Organization for Nuclear Research)” This review discusses the impact of COVID-19 on hair loss, particularly in women, and explores potential treatments, but reports no new clinical results.
June 2026 in “HAL (Le Centre pour la Communication Scientifique Directe)” This infographic compares the safety profiles of SH‑1, a cosmetic ingredient, which showed no systemic absorption, and PP405, an investigational drug with dose-dependent systemic uptake and potential threshold breaches, highlighting differences in safety between cosmetic and investigational substances according to this report.
September 2022 in “Polish Hyperbaric Research” This study analyzed 57 medicinal and cosmetic preparations available in Poland for treating alopecia, finding that finasteride is the most common active ingredient, with many products being in tablet or shampoo form and categorized as prescription drugs and cosmetics.
April 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that a shampoo containing a 6-active ingredient complex increased β-Catenin production in human hair follicle dermal papilla cells to levels comparable to Finasteride, suggesting potential for promoting hair growth. It also showed good cleaning efficacy, volume, and shine in a sensorial study.
